Mannkind (MNKD) Revenue (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.46% |
| Dec 31, 2025 | 36.31% |
| Sep 30, 2025 | 7.32% |
| Jun 30, 2025 | -2.33% |
| Mar 31, 2025 | 2.06% |
| Dec 31, 2024 | 9.56% |
| Sep 30, 2024 | -3.19% |
| Jun 30, 2024 | 9.24% |
| Mar 31, 2024 | 13.32% |
| Dec 31, 2023 | 14.09% |
| Sep 30, 2023 | 5.43% |
| Jun 30, 2023 | 19.65% |
| Mar 31, 2023 | 12.67% |
| Dec 31, 2022 | 9.85% |
| Sep 30, 2022 | 10,841.67% |
| Jun 30, 2022 | -97.50% |
| Mar 31, 2022 | -4.18% |
| Dec 31, 2021 | -43.65% |
| Sep 30, 2021 | -4.59% |
| Jun 30, 2021 | 33.52% |
| Mar 31, 2021 | -5.46% |
| Dec 31, 2020 | 20.13% |
| Sep 30, 2020 | 7,576.00% |
| Jun 30, 2020 | -98.77% |
| Mar 31, 2020 | 1.51% |
| Dec 31, 2019 | 2,184.71% |
| Sep 30, 2019 | 250.00% |
| Jun 30, 2019 | -98.85% |
| Mar 31, 2019 | 8.84% |
| Dec 31, 2018 | 258.72% |
| Sep 30, 2018 | 14.80% |
| Jun 30, 2018 | 12.35% |
| Mar 31, 2018 | -23.51% |
| Dec 31, 2017 | 121.73% |
| Sep 30, 2017 | -5.55% |
| Jun 30, 2017 | -28.12% |
| Mar 31, 2017 | -75.74% |
| Dec 31, 2016 | -92.36% |